Terms: = Lung cancer AND SMAD4, JIP, Q13485, 4089, ENSG00000141646, MADH4, DPC4 AND Clinical Outcome
3 results:
1. Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure.
Lin Z; Huang L; Li S; Gu J; Cui X; Zhou Y
Sci Rep; 2020 Dec; 10(1):21530. PubMed ID: 33299035
[TBL] [Abstract] [Full Text] [Related]
2. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
Bria E; Pilotto S; Amato E; Fassan M; Novello S; Peretti U; Vavalà T; Kinspergher S; Righi L; Santo A; Brunelli M; Corbo V; Giglioli E; Sperduti I; Milella M; Chilosi M; Scarpa A; Tortora G
Oncotarget; 2015 May; 6(14):12783-95. PubMed ID: 25904052
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcome and expression of mutant P53, P16, and smad4 in lung adenocarcinoma: a prospective study.
Bian C; Li Z; Xu Y; Wang J; Xu L; Shen H
World J Surg Oncol; 2015 Mar; 13():128. PubMed ID: 25890228
[TBL] [Abstract] [Full Text] [Related]
